Amir Iravani

Seattle Pacific University — United States

Medicine · Health Sciences

36h-index9.5kcitations174works3.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Radiopharmaceutical Chemistry and Applications(85), Prostate Cancer Treatment and Research(78), Medical Imaging Techniques and Applications(32), Neuroendocrine Tumor Research Advances(28), Cancer Immunotherapy and Biomarkers(27)

Publications172 total

Deep learning-based non-invasive profiling of tumor transcriptomes from cell-free DNA for precision oncology
2026Open Access
Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer
Clinical Cancer Research·2026
A phase 1/1b study of the theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) in patients with glypican-3-positive (GPC3+) previously treated unresectable hepatocellular carcinoma.
Journal of Clinical Oncology·2026
Rechallenge and Extended [ <sup>177</sup> Lu]Lu-PSMA Therapy in Metastatic Prostate Cancer
Journal of Nuclear Medicine·2025· 1 cited
PSMA PET-guided Intensification of Salvage Radiotherapy after Radical Prostatectomy
Radiology Imaging Cancer·2025Open Access
Consistent performance between medical experts and non‐expert readers in forced‐choice lesion‐detection tasks with PET images
Medical Physics·2025Open Access
Prostate‐specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long‐term survival
Cancer·2025
Summary: SNMMI/ACNM Procedure Standard for Posttreatment Imaging of <sup>177</sup>Lu-Based Radiopharmaceuticals
Journal of Nuclear Medicine·2025· 2 cited
Combination prostate-specific membrane antigen-targeted radiopharmaceutical therapy in metastatic prostate cancer
The Quarterly Journal of Nuclear Medicine and Molecular Imaging·2025· 2 cited
Gallbladder Neuroendocrine Tumor and 177Lu DOTATATE: High Somatostatin Receptor Expression Without Clinical Response
Clinical Nuclear Medicine·2025
NCI 10479: A phase I dose escalation-expansion trial of sunitinib malate plus lutetium (Lu-177) dotatate in somatostatin receptor positive pancreatic neuroendocrine tumors.
Journal of Clinical Oncology·2025
VALOR study: A phase II trial of vorinostat to augment response to 177Lutetium-PSMA-617 in the treatment of patients with PSMA-low metastatic castration resistant prostate cancer.
Journal of Clinical Oncology·2025· 1 cited
Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving <sup>177</sup> Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603).
Journal of Clinical Oncology·2025· 2 cited
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
Nature Medicine·2025· 18 cited
The Role of SPECT/CT in 177Lu-PSMA-617 Theranostics: Case-based Review of Response and Progression Patterns
Clinical Nuclear Medicine·2025· 2 cited
Approaches to Imaging Immune Activation Using PET
Journal of Nuclear Medicine·2025· 5 citedOpen Access
Abstract CT112: Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of FXX489 ([<i>177</i>Lu]Lu-NNS309) in patients with pancreatic, lung, breast and colorectal cancers
Cancer Research·2025· 1 cited
Beyond the <i>AJR</i> : When Nonmetastatic Disease Is No Longer Nonmetastatic
American Journal of Roentgenology·2025
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes
European Urology Oncology·2025· 5 citedOpen Access
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received<sup>177</sup>Lu-PSMA-617: Importance of<sup>18</sup>F-FDG–Avid Discordant Findings
Journal of Nuclear Medicine·2024· 7 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Michael S. Hofman(31), Rodney J. Hicks(29), Shahneen Sandhu(17), Tim Akhurst(16), Scott Williams(15), Grace Kong(13), Declan G. Murphy(11), John Violet(10), Roslyn J. Francis(9), Louise Emmett(9), David A. Pattison(8), Martin R. Stockler(8), Andrew Martin(8), Ian D. Davis(8), Natalie Rutherford(7), Ian Kirkwood(7), Aravind Ravi Kumar(7), Anthony M. Joshua(7), Arun Azad(7), Margaret McJannett(7)